

# Author Queries

Journal: Development

Manuscript: DEV146241

Please indicate your corrections using the annotation/mark-up tools and do not edit the actual text of the pdf.

Please check the **entire proof** thoroughly, paying particular attention to any text highlighted in red.

Please ensure that all tables, figures and equations are present and in the correct order.

Check carefully that the authors' names, affiliations and the corresponding author's e-mail address are correct.

**IMPORTANT:** If you submit revised figures, please let us know what has been changed in the figures so that we can check that the files have been substituted in the final proof.

**Author funding:** It is the responsibility of the corresponding author to provide the relevant funding information from **all** authors. The funding data linked to your article are summarised in a table at the end of the proof ('Funding details'). **Please check that all funders supporting your work and relevant grant numbers are included.** Funder names may have been edited to match the Crossref Open Funder Registry (see <http://search.crossref.org/funding>). Note that this table will not be included in your published paper.

**PubMed Central deposition/Self-Archiving:** We offer a free PMC deposition service to authors supported by funders that mandate PMC deposition. If you require deposition and this is not indicated in the Funding section of your proof (in the sentence starting 'Deposited in PMC for release...'), please let us know immediately. **If PMC deposition is requested at a later stage, we reserve the right to charge \$50 for the PMC deposition service.**

Authors supported by grant award bodies mandating deposition in other publicly available repositories may deposit a copy of the typeset journal PDF file for release after 12 months, or as mandated by their funder/institution, provided that it has already been published by the journal (for further information, see [Open Access rights and permissions](#)).

## Gold Open Access – CC-BY

If you have requested Gold Open Access publication, the CC-BY licence text will be displayed on page 1 of your proof, below the author affiliations. If your funder or institute mandate immediate free access, immediate release in PubMed Central and publication under a CC-BY licence, please ensure that you have selected this option.

**If a CC-BY licence is requested after publication, we reserve the right to charge an additional £200 to make this correction.**

If you selected Gold Open Access during submission but no longer require this service, please let us know as soon as possible.






Note that all other papers will be published under our Green Open Access model free of charge, and made freely available 6 months after publication. For further details, see [Open Access rights and permissions](#).

**Supplementary information:** If you have submitted supplementary data, please check that a link has been added before the references and that citations are included in the text. Please note there are no proofs for supplementary data as the files are not edited. If you wish to make any changes to your supplementary data, please provide replacement file(s).

**Author contributions:** Please provide a statement that specifies the contribution of every author listed on the article. We encourage you to use the [CRediT taxonomy](#) to define individual author contributions.

**Data availability:** All publicly available datasets supporting your work should be included in the Data availability section. Details should include repository name, identifier such as accession number or doi, and where possible a hyperlink to the URL of the dataset. For more information on our data deposition requirements, see <http://dev.biologists.org/content/journal-policies#data>.

**Please answer the hyperlinked queries below and indicate any necessary changes on the proof.**

-  Q1 Ivy Kim-Ni Chiang will be cited (e.g. in PubMed) as: Chiang, I. K.-N. Is this correct?
-  Q2 Please provide postal codes for affiliations 7 and 8. Please rationalise affiliation 5, which appears to contain two or three different affiliations.
-  Q3 The term 'restricted' must be used with caution because it is ambiguous ('restricted to' versus 'restricted in'). Thus, 'arterial endothelial cell-restricted expression' can refer to expression that is specifically suppressed in arterial endothelial cells. Please ensure that the intended meaning is clear throughout.
-  Q4 SoxF is a family term and should adopt a consistent format independent of species. The same applies to ETS.
-  Q5 Please clarify 'arteries within the vasculature'. All arteries are within the vasculature?

- Q6 Where possible, tabulated data should be presented as tables, rather than figures. Fig. 1C has been changed to Table 1.
- Q7 Fig. 1C has been changed to Table 1.
- Q8 Fig. 1C has been changed to Table 1.
- Q9 Fig. 1C has been changed to Table 1.
- Q10 Does this SOX refer to SoxF?
- Q11 Fig. 4A has been incorporated into Table 1.
- Q12 Does this SOX refer to SoxF?
- Q13 Does this SOX refer to SoxF?
- Q14 What does 'SOXFa/b' refer to? How do these sites relate to the zfSOX-a and zfSOX-b sites of the current study?
- Q15 Please clarify: 'increase in the phenotypic outcome'. Severity, frequency?
- Q16 Please check insertion of 'morphant', as this refers to *Notch1b* depletion by MO in *notch1b-15<sup>+/+</sup>* and *notch1b-15<sup>uq1mf/+</sup>* embryos?
- Q17 Please clarify: 'alone in the regulation of the Notch receptors than in the Notch ligands'.
- Q18 Please clarify: 'influence SoxF factors'. Modify their function or expression?
- Q19 Please clarify 'ETS transcription'. Does this refer to the transcription of ETS genes (e.g. *Erg*) or to that of ETS target genes (those containing ETS motifs)?
- Q20 Some rewording has been done here to avoid too many instances of 'other'.
- Q21 It is stated throughout (and illustrated in Fig. 1A) that these enhancers are from the human *NOTCH1* gene, not mouse. The full capitalisation format is also specific to the human gene symbol: *notch1b* zebrafish, *Notch1* mouse, *NOTCH1* human. The prefix 'hm' also refers to human. There is no indication of mouse analysis until the last section of the Results. Please clarify why it states here that the sequences were generated from mouse genomic DNA (e.g. are the mouse and human sequences identical)?
- Q22 X-Gal is a substrate and hence it is incorrect to refer to mice as expressing X-Gal; this has been changed to *lacZ*.
- Q23 The allele description *uq1mf/1mf* has been changed to *uq1mf/uq1mf*.
- Q24 Please clarify: 'treated'.
- Q25 Some of this Materials and Methods text is repeated in the supplementary Materials and Methods without any additional detail. Please remove unnecessary redundancy from either the main or supplementary text (no sentences were marked for deletion among the supplementary corrections that you provided).
- AQ26 Please check that the BIOBASE url is correct.
- Q27 The allele description *uq1mf/1mf* has been changed to *uq1mf/uq1mf*.
- Q28 Authors funded by the UK Medical Research Council or Biotechnology and Biological Sciences Research Council must wish to check their funders' open access policies. Development papers are made freely available 6 months after publication.
- Q29 Please check the funding section. Funders may have been edited in order to exactly match the CrossRef funder registry (<http://search.crossref.org/fundref>). The funding table at the end of your proof will be deleted before publication.
- Q30 Please insert the repository name and accession number for the ChIP-seq data deposit.
- Q31 The majority of the figures are at 100% of the size at which they were provided. If some figures appear too small in the proofs then you will need to resupply larger versions but maintain necessary resolution.
- Q32 Fig. 4B, please explain the difference between the left and right images of each pair.
- Q33 Please provide a new version of Fig. 5 in which the SOX18 ChIP-seq track is relabelled SOX18Ragged ChIP-seq in A.
- Q34 Fig. 6C. 'See A' has been added because this is the only place where zfETS-a and zfETS-b are referred to in the text.
- Q35 Fig. 7A legend. Please check added text: 'All panels show composite images'.
- Q36 Fig. 8 legend. The correct format is *uq1mf/+*, not *uq<sup>1mf/+</sup>*, as that would indicate *1mf* and WT alleles of a gene called *uq*.
- Q37 The allele description *uq1mf/1mf* has been changed to *uq1mf/uq1mf*.
- Q38 In Fig. 9A, 8.5dpc should be E8.5.
- Q39 Please check Table 1 (redrawn from Fig. 1C and Fig. 4A), including the title and footnotes.

I was cited as  
Chiang I. K. in  
pubmed

# SoxF factors induce Notch1 expression via direct transcriptional regulation during early arterial development

Ivy Kim-Ni Chiang<sup>1,\*</sup>, Martin Fritzsche<sup>2,\*</sup>, Cathy Pichol-Thievend<sup>1</sup>, Alice Neal<sup>2</sup>, Kelly Holmes<sup>3</sup>, Anne Legendijk<sup>1</sup>, Jeroen Overman<sup>1</sup>, Donatella D'Angelo<sup>4</sup>, Alice Omini<sup>4</sup>, Dorien Hermkens<sup>5</sup>, Emmanuelle Lesieur<sup>1</sup>, Ke Liu<sup>6</sup>, Indrika Ratnayaka<sup>2</sup>, Monica Corada<sup>7</sup>, George Bou-Gharios<sup>6</sup>, Jason Carroll<sup>3</sup>, Elisabetta Dejana<sup>7,8</sup>, Stefan Schulte-Merker<sup>5</sup>, Benjamin Hogan<sup>1</sup>, Monica Beltrame<sup>4</sup>, Sarah De Val<sup>2,‡</sup> and Mathias Francois<sup>1,‡</sup>

## ABSTRACT

Arterial specification and regulation by a number of transcription factors plays a central role, the transcriptional hierarchy controlling arterial specification has not been fully delineated. To elucidate the direct transcriptional regulators of Notch receptor expression in arterial endothelial cells, we used histone signatures, DNase-seq hypersensitivity and ChIP-seq data to identify enhancers for the human *NOTCH1* and zebrafish *notch1b* genes. These enhancers were able to direct arterial endothelial cell-restricted expression in transgenic models. Genetic disruption of SoxF binding sites established a clear requirement for members of this group of transcription factors (SOX7, SOX17 and SOX18) to drive the activity of these enhancers *in vivo*. Endogenous deletion of the *notch1b* enhancer led to a significant augmentation of arteriovenous defects in Notch pathway-deficient zebrafish. Loss of SoxF function revealed that these factors are necessary for *NOTCH1* and *notch1b* enhancer activity and for correct endogenous transcription of these genes. These findings position SoxF transcription factors directly upstream of Notch receptor expression during the acquisition of arterial identity in vertebrates.

**KEY WORDS:** Notch1, SoxF, Artery, Arterial enhancer, Endothelial cell, Transcriptional regulation, Zebrafish, Human, Mouse

## INTRODUCTION

Genetic specification of arterial fate has long been attributed to regulation downstream of the Vegfa and Notch pathways. Vegfa signalling is essential for arterial specification in both zebrafish and mammalian models, at least partially by stimulating the expression of components of the Notch pathway, while activation of Notch signalling can rescue defects in Vegfa-deficient zebrafish embryos

(Lanahan et al., 2010; Lawson et al., 2002; Liu et al., 2003; Visconti et al., 2002). The Notch receptors Notch1 and Notch4 and the delta-like ligands Dll1, Dll4, Jag1 and Jag2 are expressed in endothelial cells, where they play crucial roles in both arteriogenesis and angiogenesis (Lawson et al., 2002; Liu et al., 2003; Phng and Gerhardt, 2009; Roca and Adams, 2007). Ligand binding to the Notch receptor releases the Notch intracellular domain (NICD), which translocates to the nucleus and forms a transcriptional activation complex with the otherwise repressive DNA-bound Rbpj [CSL, Su(H)] (Bray, 2006). Combined ablation of Notch1 and Notch4, which are both principally expressed in arterial endothelial cells during early vascular remodelling (Chong et al., 2011; Jahnsen et al., 2015), results in severe vascular remodelling defects (Krebs et al., 2000), as does ablation of the Notch downstream effector Rbpj or of Dll4, a Notch ligand specific to arteries within the vasculature (Duarte et al., 2004; Gale et al., 2004; Krebs et al., 2004). However, loss of Notch signalling does not fully recapitulate the arterial defects downstream of Vegfa ablation (Carmeliet et al., 1996; Krebs et al., 2000; Lawson et al., 2002), and the arterially restricted gene expression patterns of components of the Notch pathway do not fully overlap with activated Vegfa (Lawson, 2003), suggesting that additional factors are involved in the regulation of Notch-mediated arterial fate.

The SoxF group of transcription factors (Sox7, Sox17 and Sox18) are expressed in endothelial cells from early in development (Francois et al., 2010). While each SoxF member displays a subtly different endothelial expression pattern, all three factors are expressed early in arterial development (Corada et al., 2013; François et al., 2008; Zhou et al., 2015) and share considerable functional redundancy, complicating interpretation of the consequences of gene disruption (Hosking et al., 2009; Zhou et al., 2015). Combined loss of *sox7* and *sox18* in zebrafish, both by morpholino-based knockdown and genetic mutation, resulted in serious arteriovenous malformations similar to those seen after Notch ablation, suggesting that SoxF factors might genetically interact with the Notch pathway in endothelial cells (Cermenati et al., 2008; Hermkens et al., 2015; Herpers et al., 2008; Lawson et al., 2001). Further evidence was provided in mice, where endothelial-specific ablation of *Sox17* caused arterial differentiation and remodelling defects (Corada et al., 2013), and conditional deletion of SoxF factors in the adult resulted in loss of major vessel identity in the retina (Zhou et al., 2015). Inhibition of Vegfa signalling can significantly impact SoxF expression and activity in both mouse and zebrafish models (Kim et al., 2016; Pendeville et al., 2008; Duong et al., 2014; Pennisi et al., 2000b), suggesting that members of the SoxF family lie downstream of Vegfa. Further, SoxF acts in a positive feed-forward loop to maintain *Flk1* (*Kdr*; *kdr1* in zebrafish) expression (Kim et al., 2016). By contrast,

<sup>1</sup>Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland 4072, Australia. <sup>2</sup>Ludwig Institute for Cancer Research, Nuffield Department of Clinical Medicine, The University of Oxford, Oxford OX3 7DQ, UK.

<sup>3</sup>Cancer Research UK, The University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE, UK. <sup>4</sup>Dipartimento di Bioscienze, Università degli Studi di Milano, Via Celoria 26, 20133 Milano, Italy. <sup>5</sup>University of Münster, 48149 Münster, Germany Institute for Cardiovascular Organogenesis and Regeneration, Faculty of Medicine, Westfälische Wilhelms-Universität Münster (WWU), Mendelstrasse 7, 48149 Münster and CIM Cluster of Excellence, Germany.

<sup>6</sup>Institute of Aging and Chronic Disease, University of Liverpool, Liverpool L69 3GA, UK. <sup>7</sup>IFOM, FIRC Institute of Molecular Oncology, Milan, Italy. <sup>8</sup>Department of Immunology Genetics and Pathology, Uppsala University, Uppsala, Sweden. \*These authors contributed equally to this work

<sup>‡</sup>Authors for correspondence (sarah.deval@ludwig.m.francois@imb.uq.edu.au)

DOI: 10.1242/dev.146241

Received 28 October 2016; Accepted 7 June 2017

this affiliation was provided as is by Stefan Schulte-Merker- please keep it like this

<sup>‡</sup>IFOM, FIRC Institute of Molecular Oncology, 1620139 Milan, Italy. <sup>‡</sup>Department of Immunology Genetics and Pathology, Uppsala University, 75185 Uppsala, Sweden.

the ablation of Notch signalling in the vasculature does not significantly impact the expression of SoxF (Abdelilah et al., 1996; Corada et al., 2013). Different experimental models have positioned SoxF genes both upstream (Corada et al., 2013) and downstream (Lee et al., 2014) of Notch signalling in endothelial cells, suggesting a complex relationship between these two pathways.

Analysis of the only known enhancers for the Notch pathway, namely the arterial-specific *Dll4*-12 (Sacilotto et al., 2013) and *Dll4*in3 enhancers (Sacilotto et al., 2013; Wythe et al., 2013), has demonstrated a crucial role for SoxF factors in the regulation of expression of the Notch ligand *Dll4* in arteries, in combination with Rbpj/Notch binding and in the presence of ETS factors including Erg (Sacilotto et al., 2013; Wythe et al., 2013). Although this work clearly positioned the SoxF and Notch pathways as crucial regulators of arterial specification, and is supported by analysis placing Sox17 upstream of Notch signalling in mouse models (Corada et al., 2013), ablation of arterial marker expression only occurs after the removal of both SoxF factors and Notch signalling in combination (Sacilotto et al., 2013). Consequently, the precise transcriptional hierarchy of SoxF and Notch has yet to be fully established. Although studies of the Notch receptor genes *Notch1* and *Notch4* also identified SoxF binding motifs within putative promoter sequences (Corada et al., 2013; Lizama et al., 2015), a requirement for these SoxF motifs in arterial-specific gene expression of Notch receptors has not been established. In this study, we have identified and characterised arterial-specific


enhancers directing *NOTCH1/notch1b* gene expression *in vivo*, and used them to demonstrate a direct requirement for SoxF factors in the transcriptional regulation of Notch receptors during early arterial differentiation, positioning SoxF factors upstream of Notch in the acquisition of arterial cell identity.

### RESULTS

#### Identification of an arterial-specific NOTCH1 intronic enhancer

Previous studies into the transcriptional regulation of the Notch receptors have not extended to the identification or analysis of gene enhancers (cis-regulatory elements) (Corada et al., 2013; Lizama et al., 2015; Wu et al., 2005). We therefore conducted a detailed *in silico* analysis of the *NOTCH1* locus with the aim of identifying novel, arterial-specific enhancers. This analysis focused on human *NOTCH1* in order to take advantage of the wealth of publicly available information describing chromatin modifications in human endothelial cell lines. Using this information, we were able to pinpoint four regions of DNA rich in endothelial cell-specific H3K4me1 and H3K27ac histone modifications and DNaseI digital genomic footprints, all marks closely associated with enhancer activity (Heintzman and Ren, 2009; Sabo et al., 2004) (Fig. 1A, Fig. S1).

The putative enhancer regions were named *NOTCH1*+33, *NOTCH1*+16, *NOTCH1*+3/5 and *NOTCH1*-68 to reflect their distance from the transcription start site (TSS) in kb. Each enhancer region was cloned upstream of the silent *hsp68* minimal promoter



**Fig. 1. The human *NOTCH1* locus contains multiple putative endothelial enhancers.** (A) The human *NOTCH1* locus from UCSC ENCODE Genome Browser (<http://genome.ucsc.edu>). Human umbilical vein endothelial cell (HUVEC)-specific H3me1 and H3K27ac (enhancer associated) and H3K4me3 (promoter associated) peaks are indicated in light blue [both in the separate HUVEC and combined tracks (denoted as 'all')]; other colours indicate H3K4me1, H3K4me3 and H3K4ac peaks specific to non-endothelial cell lines: GM12878 cells (red), H1-hESC cells (yellow), HSMM cells (green), K562 cells (purple) NHEK cells (lilac) and NHLF cells (pink). *INPP5E* and *SEC16A* are shown (blue text) in addition to *NOTCH1* (black text). DNase I digital hypersensitive hotspots are indicated by black vertical lines on grey (HUVEC, HMVEC-dBI-Ad, HMVEC-dBI-Neo and HMVEC-LBI, which are all different endothelial cell types). The four *NOTCH1* putative enhancer regions (black bars) were identified by high levels of HUVEC-specific H3K4me1 and H3K27ac associated with endothelial cell-specific DNaseI hypersensitivity hotspots. P, putative promoters identified by H3K4me3. (B) The human *NOTCH1* gene (top, in 5' to 3' orientation with putative enhancers indicated) and the *NOTCH1*+16hsp transgene (bottom).



**Table 1. Reporter gene expression patterns in E12 mice transgenic for each putative *NOTCH1* enhancer region and the effects of SoxF motif mutation on *NOTCH1+16* enhancer activity**

Transgene	n	Arterial expression	<i>lacZ</i> in AECs	<i>lacZ</i> in VECs
<i>NOTCH1-68</i>	5	3	0	0
<i>NOTCH1+3/5</i>	4	4	0	0
<i>NOTCH1+16</i>	10	9	6	0
<i>NOTCH1+33</i>	5	5	1	1
<i>NOTCH1+16 WT</i>	8	7	4	0
<i>NOTCH1+16mutSOX-alb</i>	9	6	0*	0*


\*Faint vascular expression was detected in section analysis but was not visible in whole-mount analysis. n, number of transgenic mice analysed. AECs, arterial endothelial cells; VECs, venous endothelial cells.

and the *lacZ* reporter gene (Fig. 1B) and tested for its ability to drive reporter gene expression specifically in arterial endothelial cells of transient transgenic mice at embryonic day (E) 12-13. Although each of the four putative enhancer regions was able to drive detectable levels of *lacZ* in transgenic mice, this expression was primarily neural, an expression pattern commonly seen when using the *hsp68* minimal promoter (e.g. Becker et al., 2016; Sacilotto et al., 2013) (Table 1, Fig. S2). Only the *NOTCH1+33* and *NOTCH1+16* enhancers were able to direct expression in endothelial cells (Table 1, Fig. S2). In the case of *NOTCH1+33*, vascular expression was detected in only one of the five transgenic mice analysed. This expression was not restricted to the arterial endothelium but was pan-endothelial (Table 1, Fig. S2). This agrees with previous reports indicating that the mouse orthologue of this region, termed *Notch1\_enh1*, also directs occasional vascular enhancer activity but did not show arterial-specific expression (Zhou et al., 2017). Conversely, the 274 bp *NOTCH1+16* enhancer was able to robustly direct expression specifically to arterial endothelial cells within the vasculature at E12 in multiple independent transgenic embryos (Table 1, Fig. 2 and Fig. S2). This indicates that the *NOTCH1+16* enhancer represents a novel, arterially restricted enhancer within the *NOTCH1* locus. Analysis of a stable mouse line expressing the *NOTCH1+16:lacZ* transgene clearly demonstrated that this enhancer is strongly active from the very early stages of vascular development, mimicking the expression of endogenous Notch by becoming restricted to the arteries by late E9.5 and then maintaining an arterial endothelial cell-restricted expression pattern throughout embryonic development (Chong et al., 2011; Jahnsen et al., 2015) (Fig. 2).

**The *NOTCH1+16* enhancer is bound and regulated by SoxF factors**

To identify the transcription factors that potentially regulate the *NOTCH1+16* enhancer, we performed a ClustalW analysis of orthologous mammalian sequences (Fig. 3A). This analysis clearly identified nine conserved core consensus ETS binding motifs [GGAW (Hollenhorst et al., 2011)] and two consensus SOX binding motifs [WWCAAW (Mertin et al., 1999)] (Fig. 3A) within the 274 bp *NOTCH1+16* enhancer. Because not all *in silico* consensus binding motifs are able to functionally bind the cognate protein, these motifs were then tested by electrophoretic mobility shift assay (EMSA). Both SoxF motifs (termed hmSOX-a and hmSOX-b) were able to bind recombinant SOX7 and SOX18 proteins in EMSA (Fig. 3B), and three ETS motifs (termed hmETS-a, hmETS-b and hmETS-c) were able to bind the endothelial ETS protein ETV2 (Fig. 3C).

ETS motifs are common to all endothelial-expressed gene enhancers (De Val and Black, 2009). Although the ETS factor Erg



**Fig. 2. The *NOTCH1+16* transgene directs arterial endothelial cell-restricted expression in transgenic mice.** (A-N) Representative transgenic whole-mount embryos (A-H) and transverse sections (I-N) showing *lacZ* reporter gene expression ( $\beta$ -galactosidase detected by blue X-gal staining) in arterial endothelial cells throughout embryonic development. The boxed region in J is magnified in K. (O,P) E12 transverse section showing that expression of the venous marker endomucin (Emcn) does not overlap with *lacZ* reporter gene expression on the same section. cv, cardinal vein; da, dorsal aorta; en, midline dorsal aorta; mda, midline dorsal aorta; uv, umbilical vein; v, vein.


has been implicated in previous studies have expression of the arterial additional transcription factors Sacilotto et al., 2013; alone are unlikely to be

To test whether the SoxF motifs play a role in *NOTCH1+16* enhancer activity, we mutated the core nucleotides of these motifs (see Materials and Methods for sequences) and tested the ability of the resultant *NOTCH1+16mutSOX-a/b* enhancer to drive reporter gene expression. Strikingly, enhancer mutation resulted in a dramatic reduction in reporter gene expression in endothelial cells in transgenic mice, although transgene expression was detected outside of the vascular system (Fig. 4, Table 1). This result differs notably from that reported for the *Dll4* enhancers, where mutations in SoxF motifs, or loss of SoxF factors, resulted in no detectable decrease in *Dll4* expression unless accompanied by ablation of Notch signalling (Sacilotto et al., 2013).

**Zebrafish *notch1b* is directly transcriptionally regulated by SoxF factors via an evolutionarily non-conserved enhancer**


The SoxF-dependent *NOTCH1+16* enhancer robustly directed arterial-restricted expression in transgenic mouse models. However, this enhancer did not exhibit sequence conservation beyond

it refers to SOX family as a whole, not just SOXF



**Fig. 3. The *NOTCH1+16* enhancer contains *SoxF* and ETS binding motifs.** (A) Multispecies alignment of the orthologous region of the *NOTCH1+16* enhancer from human, mouse and opossum (oposs) using ClustalW. Coloured sequences are confirmed by EMSA; grey sequences are motifs identified *in silico* that did not bind in EMSA. (B) Radiolabelled oligonucleotide probes encompassing *NOTCH1+16* hmSOX-a (lanes 1-8) and hmSOX-b (lanes 9-16) were bound to recombinant SOX7 (lanes 2-4 and 10-12) and SOX18 (lanes 6-8 and 14-16). Both proteins, which efficiently bound labelled probes (lanes 2, 6, 10 and 14), were competed by excess unlabelled self-probe (WT, lanes 3, 7, 11 and 15) but not by mutant self-probe (MT, lanes 4, 8, 12 and 16). (C) Radiolabelled oligonucleotide probes encompassing *NOTCH1+16* hmETS-a (lanes 17-20), hmETS-b (lanes 21-24) and hmETS-c (lanes 25-28) were bound to recombinant ETV2 protein. ETV2, which efficiently bound to labelled probes (lanes 18, 22 and 26), was competed by excess unlabelled self-probe (WT, lanes 19, 23 and 27) but not by mutant self-probe (MT, lanes 20, 24 and 28).

mammals (Fig. S1B), leaving it unclear how relevant these observations are to Notch signalling during arteriovenous specification in zebrafish, an extremely well-studied model system (Gore et al., 2012). We therefore investigated whether *SoxF* factors were able to transcriptionally regulate the zebrafish orthologue of *NOTCH1*, *notch1b*, by examining the binding patterns of the zebrafish *SoxF* transcription factors around the *notch1b* locus. Zebrafish *SoxF* are expressed in early endothelial cells and implicated in arteriovenous differentiation (Cermenati et al., 2008; Hermkens et al., 2015; Herpers et al., 2008; Pendeville et al., 2008). To probe for *SoxF* (Sox7, Sox17 and Sox18) genome-wide binding locations we used an endothelial-specific SOX18Ragged overexpression line. The SOX18Ragged dominant-negative protein has been shown to interfere with the endogenous function of all three *SoxF* transcription factors (xxxxx citation? xxxxx). Using 26-28 hours post fertilisation (hpf) embryos from the *tg(fli1a:Gal4FF;10xUAS:Sox18Ragged-mCherry)* zebrafish line, in which a tagged SOX18Ragged is expressed specifically in endothelial cells (Fig. S3A), ChIP-seq analysis identified a *SoxF* binding event 15 kb upstream of the *notch1b* first exon (Fig. 5A). This binding peak was enriched in the enhancer-associated histone modifications H3K4me1 and H3K27ac at 24 hpf (Bogdanović et al., 2012; Kent et al., 2002) (Fig. 5A), suggesting that it might represent a novel enhancer of *notch1b*. A 1219 bp zebrafish DNA fragment corresponding to the SOX18-bound region, termed the *notch1b-15* enhancer, was cloned upstream of a silent *gata2a*



**Fig. 4. *SoxF* factors are required for *NOTCH1+16* activity.** (A) Four representative whole-mount E12 X-gal-stained embryos transgenic for the *NOTCH1+16mutSOX-a/b* construct. Numbers at the bottom left indicate the unique embryo identifier. (B) Transverse sections taken from two *NOTCH1+16mutSOX-a/b* embryos demonstrate the very limited endothelial expression detected in these embryos (asterisks).

promoter and *GFP* reporter gene within the zebrafish enhancer detection (ZED) vector (Bessa et al., 2009) (Fig. 5B) and used to generate the stable *tg(notch1b-15:GFP)* fish line (Fig. 5C). The *GFP* transcript was detected in the vascular cord around the midline from 19 hpf, and persisted in the vascular rod as it formed the dorsal aorta at 22 hpf (Fig. 5C). *GFP* expression continued to be restricted to the dorsal aorta and the segmental arteries in larvae from 24 hpf until 48 hpf. This arterial-restricted pattern of expression within the vasculature was similar to that of endogenous *notch1b* (Fig. S3B), indicating that the SOX18-bound *notch1b-15* element is a bona fide *notch1b* enhancer and suggesting that *SoxF* factors directly transactivate Notch receptor transcription in arterial endothelial cells in zebrafish.


ClustalW analysis comparing the orthologous enhancer sequences from fugu, stickleback and medaka revealed a remarkably similar pattern of conserved transcription factor motifs when compared with the *NOTCH1+16* enhancer (Fig. 6A), with multiple ETS and two SOX binding motifs, termed zfSOX-a and zfSOX-b, confirmed by EMSA analysis (Fig. 6B,C). To establish whether the zfSOX-a and zfSOX-b binding motifs were required for *notch1b-15* arterial enhancer function, we generated transient transgenic fish lines harbouring mutated SOX binding motifs (*notch1b-15mutSOX-a/b:GFP*) and compared the activity of the transgene with wild-type (WT) *notch1b-15:GFP* control transient transgenic animals (Fig. S4A,B). Simultaneous disruption of both zfSOX-a and zfSOX-b sites led to a reduction of arterial-specific *GFP* expression in endothelial cells. Although a minority of mutant fish still expressed *GFP* after *SoxF* binding site mutation, the loss of expression was still much greater than that seen after *SoxF* motif mutation in a previously published *Dll4* enhancer in transgenic zebrafish where vascular expression rates were unaffected by *SoxF* mutation (Sacilotto et al., 2013), supporting a key role for *SoxF* factors in *notch1b* activation. To further confirm our observation, we established stable transgenic *notch1b-15mutSOX-a/b:GFP* fish lines and compared them with the established WT *notch1b-15:GFP* lines. Analysis of the stably transgenic embryos (Fig. 7A) confirmed a *GFP* expression pattern in the dorsal aorta and segmental arteries for the WT transgene. By contrast, the *tg*

4 Do you think this look weird?Mat? I think people refer it as SOX18 ragged, or just ignore it.

Please cite:James et al., 2003 (PMID: 12748961)and Pennisi et al 2000 (PMID: 10742113). Please add on and check

It is referring to the 2 SOX sites also identified in Dll4 enhancer, in terms of location, they are not related to zfSOX-a/b






**Fig. 5. A SOX18-bound region within the *notch1b* locus represents a bona fide arterial-specific enhancer.** (A) Part of the zebrafish *notch1b* locus from the UCSC ENCODE Genome Browser. The *notch1b* gene is in 3' to 5' orientation, H3K27ac peaks at 24 hpf are in purple, H3K4me1 peaks at 24 hpf are blue, SOX18 ChIP-seq peaks are red, and the region encompassing the *notch1b-15* enhancer is indicated by the purple horizontal bar. (B) The ZED *notch1b-15:GFP* transgene. Ins, insulator sequences; GATA2 prom, the silent GATA2 promoter; ZED control:RFP, the active cardiac actin enhancer/promoter construct fused to the RFP gene used as a positive control in the ZED vector. (C) The *notch1b-15:GFP* transgene directs arterial endothelial cell-specific expression in the zebrafish line *tg(notch1b-15:GFP)*. Representative transgenic whole-mount embryos and transverse sections show reporter gene expression, as detected by *in situ* hybridisation (top row, blue) or GFP fluorescence (bottom rows, green) in arterial endothelial cells throughout embryonic development. nt, neural tube; nc, notochord; DA, dorsal aorta; PCV, posterior cardinal vein; aISV (arrows), arterial intersomitic vessel; DLAV, dorsal longitudinal anastomotic vessel.

(*notch1b-15mutSOX-a/b:GFP*) lines showed ectopic GFP expression in neurons and a significant decrease of GFP expression in the arterial endothelium (Fig. 7A). Quantitative analysis of GFP intensity in both dorsal aorta and segmental arteries showed lower expression in most *tg(notch1b-15mutSOX-a/b:GFP)* than in WT *tg(notch1b-15:GFP)* embryos (Fig. 7B,C, Fig. S4C). Taken together, these data clearly demonstrate that the *zfSOX-a/b* binding sites are required to guide *notch1b-15*-specific enhancer activity *in vivo* during arterial development.

We next investigated the consequences of morpholino (MO)-based knockdown of SoxF on *tg(notch1b-15:GFP)* fish. *sox7/sox18* double morphants exhibit a severe vascular phenotype (Fig. S5), including fusions and shunts between the dorsal aorta and cardinal vein (Cermenati et al., 2008; Herpers et al., 2008; Pendeville et al., 2008), phenotypes that are shared with *sox7;sox18* double-mutant fish (Hermkens et al., 2015). MO-induced transcript depletion of



**Fig. 6. The *notch1b-15* enhancer contains essential Sox binding motifs.**


(A) Multispecies alignment of the orthologous regions of the *notch1b-15* enhancer from zebrafish (*zf*), fugu, stickleback (*stickle*) and medaka using ClustalW. Coloured sequences are confirmed by EMSA; grey sequences are motifs identified *in silico* that did not bind robustly in EMSA. (B) Radiolabelled oligonucleotide probes encompassing *notch1b-15* *zfSOX-a* (lanes 1-8) and *zfSOX-b* (lanes 9-16) were bound by recombinant SOX7 (lanes 2-4 and 10-12) and SOX18 (lanes 6-8 and 14-16). Both proteins, which efficiently bound labelled probes (lanes 2, 6, 10 and 14), were competed by excess unlabelled self-probe (WT, lanes 3, 7, 11 and 15) but not by mutant self-probe (MT, lanes 4, 8, 12 and 16). (C) Radiolabelled oligonucleotide probes encompassing *notch1b-15* *zfETS-a* (lanes 17-20) and *zfETS-b* (lanes 21-24) (see A) were bound by recombinant ETV2 proteins. ETV2, which efficiently bound to labelled probes (lanes 18 and 22), was competed by excess unlabelled self-probe (WT, lanes 19 and 23) but not by mutant self-probe (MT, lanes 20 and 24).

*sox7* or *sox18* resulted in downregulation of *notch1b-15:GFP* expression, while *sox7/sox18* double-morphant *tg(notch1b-15:GFP)* fish demonstrated a near-complete loss of reporter gene expression (Fig. 7D,E).

Taken together, these results indicate that SoxF proteins directly modulate the activity of arterial-specific enhancers for both the mammalian NOTCH1 and zebrafish Notch1b receptors, positioning SoxF transcription factors directly upstream of Notch signalling during early arterial differentiation in both mammals and zebrafish.

### Loss of endogenous *notch1b-15* enhancer activity perturbs *notch1b* transcription and causes arteriovenous defects


To assess whether the endogenous *notch1b-15* regulatory element is functionally relevant during arteriovenous differentiation *in vivo*, we deleted the endogenous *notch1b-15* enhancer in zebrafish. The resultant *notch1b-15<sup>uq1mf</sup>* allele was generated using two guide RNAs to drive rapid genome editing using the CRISPR/Cas9 system (Fig. 8A), resulting in excision of a 203 bp fragment overlapping the *notch1b-15* enhancer. Analysis of endogenous *notch1b* expression in the F<sub>2</sub> generation demonstrated lower *notch1b* expression levels in both dorsal aorta and arterial intersomitic vessel (aISV) of the *notch1b-15<sup>uq1mf/uq1mf</sup>* homozygous embryos as compared with their sibling controls, whereas no change was observed in the neural tube (Fig. 8B). Next, we assessed the *notch1b* transcript levels in purified *flt1*-positive arterial endothelial cell populations from the F<sub>3</sub>



**Fig. 7. Sox factors are required for *notch1b-15* activity.** (A) Confocal projection of stably transgenic WT *tg(notch1b-15:GFP)* (left) and *tg(notch1b-15mutSOX-a/b:GFP)* (right), where both *zfsOX-a* and *zfsOX-b* sites have been simultaneously mutated. Representative larvae from four independent founders are shown. Asterisks indicate the reduced GFP expression in the dorsal aorta. Arrowheads show the ectopic neuronal expression observed in *tg(notch1b-15mutSOX-a/b:GFP)*. All panels show composite images. (B,C) The intensity of GFP expression in the dorsal aorta and arterial intersomitic vessels of the stably transgenic *tg(notch1b-15:GFP)* and *tg(notch1b-15mutSOX-a/b:GFP)* at 2 dpf. Expression is normalised to GFP genomic copy number. Mean  $\pm$  s.e.m. *tg(notch1b-15)*,  $n=41$ ; *tg(notch1b-15mutSOX-a/b:GFP)*,  $n=29$ . \*\*\*\* $P<0.0001$  (Mann-Whitney U-test). (D) Levels of GFP expression in *tg(notch1b-15:GFP)* zebrafish embryos after MO injection. Number of fish for each condition is indicated. (E) Representative examples of *sox7/18* double-morphant *tg(notch1b-15:GFP)* zebrafish at 24 hpf as compared with uninjected controls. Double morphants (dMO) demonstrated reduced EGFP expression in the dorsal aorta and intersomitic vessels. DA, dorsal aorta; PCV, posterior cardinal vein; aISV, arterial intersomitic vessel.

generation of homozygous fish ( $F_2$  *notch1b-15<sup>uq1mf</sup>* homozygous in-cross) compared with WT control larvae ( $F_2$  *notch1b-15<sup>+/+</sup> × flt1:YFP;lyve1:dsRed*) at 24–28 hpf (Fig. 8C). As expected, *notch1b* transcripts were significantly downregulated in the homozygous animals, strongly supporting a role for the *notch1b-15* enhancer in the transcription of endogenous *notch1b* in arterial endothelial cells.

To assess the phenotypic outcome of *notch1b-15* loss of function, we took advantage of the *tg(notch1b-15<sup>uq1mf</sup>);flt1:YFP;lyve1:dsRed* line to analyse the developing vasculature after *notch1b-15* enhancer deletion in both the  $F_2$  and  $F_3$  generations. Surprisingly, given the reduced levels of *notch1b* (Fig. 8B), no overt vascular phenotype was detected in  $F_2$  *notch1b-15<sup>uq1mf</sup>uq1mf* homozygous zebrafish ( $F_1$  homozygous in-cross) (Fig. S6A), suggesting partial enhancer redundancy. Such redundancy, which is potentially explained by the pervasiveness of redundant, or ‘shadow’,



**Fig. 8. Loss of endogenous *notch1b-15* compromises artery formation and reduces the endogenous *notch1b* transcript level.** (A) The deleted region (dashed line) of *notch1b-15* mutant allele *uq1mf*, which includes both the *zfsOX-a* and *zfsOX-b* sites (yellow). (B)  $F_2$  *notch1b-15<sup>uq1mf</sup>uq1mf* has reduced *notch1b* expression in dorsal aorta and intersomitic vessels (white arrows) as compared with sibling WT and heterozygotes (black arrows) at 26–28 hpf. The number of embryos showing the illustrated phenotype among the total examined is indicated. (C) Quantitative PCR on FACS-sorted endothelial populations at 24–28 hpf, showing that  $F_3$  *notch1b-15<sup>uq1mf</sup>uq1mf* fish have lower *notch1b* expression than WT fish. Expression is relative to *kdrl* and *flt1*. Mean  $\pm$  s.e.m. *uq1mf* and  $n=8$  (WT) independent sorts, where each sort contains 100 larvae; \* $P<0.05$ , \*\*\* $P<0.001$  (t-test). (D) The experimental timeline to characterise the vascular phenotype of the mutant 1 (T1, red), *notch1b* MO was injected at the 1–2 cell stage. Vasculature of each embryo was then analysed blindly at 3 dpf. After scoring, genotypes were assigned to each larva. In treatment 2 (T2, blue), larvae from the *uq1mf* cross were treated with or without DAPT (5  $\mu$ M) from 15–16 hpf until 3 dpf. Vessels of these treated larvae were blindly scored prior to genotyping, as reported for T1. (E) At 3 dpf, *notch1b-15<sup>uq1mf</sup>uq1mf* *notch1b* morphants frequently showed ectopic sprouting between the intersomitic vessels (asterisks) as compared with sibling WT *notch1b* morphants. Mutants also show loss of arterial connections (red arrowheads) between the dorsal longitudinal anastomotic vessel (DLAV) and dorsal aorta (DA), as indicated by the loss of YFP expression in the *tg(flt1:YFP)* background. (F) (Top) Quantification of hypersprouting ISV number in individual *notch1b* morphants labelled by *tg(flt1:YFP)* at 3 dpf. Mean  $\pm$  s.e.m. Sibling WT,  $n=20$ ; heterozygote (*uq1mf*),  $n=32$ ; homozygous mutant (*uq1mf*),  $n=21$ . (Bottom) Quantification of YFP-positive intersomitic vessels that connect between DLAV and DA in individual *notch1b* morphants labelled by *tg(flt1:YFP)* at 3 dpf. Mean  $\pm$  s.e.m. Sibling WT,  $n=20$ ; heterozygote,  $n=32$ ; homozygous mutant,  $n=21$ . \*\* $P<0.005$  (Mann–Whitney U-test). (G) Quantification of YFP-positive intersomitic vessels that connect between DLAV and DA in individual embryos treated with 5  $\mu$ M DAPT at 3 dpf. Vessels are labelled by *tg(flt1:YFP)*. Mean  $\pm$  s.e.m. Sibling WT,  $n=9$ ; heterozygote,  $n=25$ ; homozygous mutant,  $n=14$ . \* $P<0.05$  (Mann–Whitney U-test).

enhancers around developmental genes (Cannavò et al., 2016), has previously been well documented in key endothelial genes, with examples including the *Dll4*, *Flk1* and *Tall1* loci (Cannavò et al.,



2016). By contrast, we detected a subpopulation (20-30%) of larvae from the F<sub>3</sub> generation (F<sub>2</sub> homozygous *notch1b-15<sup>uq1mf/1mf</sup>* in-cross) that displayed a phenocopy of the *notch1b* loss-of-function phenotype (Fig. S6B). This increase in the phenotypic outcome in the F<sub>3</sub> generation suggests that, in the context of the *notch1b-15<sup>uq1mf/+</sup>* cross, maternal mRNA deposition is likely to help compensate for the disruption of *notch1b* transcription caused by deletion of the *notch1b* enhancer, a compensation that is reduced in a purer *notch1b-15<sup>uq1mf/1mf</sup>* genetic background (Harvey et al., 2013).

To bypass potential rescue effects of shadow enhancers or maternally deposited transcripts, we also investigated arteriovenous differentiation and sprouting angiogenesis in F<sub>2</sub> *notch1b-15<sup>uq1mf/1mf</sup>* zebrafish after low-level depletion of *notch1b* mRNA. A splice *notch1b* MO was injected into eggs from a *notch1b-15<sup>uq1mf/+</sup>* in-cross in the *tg(flt1:YFP;lyve1:dsRed)* background. The *notch1b* MO was used at suboptimal concentration (5 ng/embryo), which is known to result in minimal phenotypes (Sacilotto et al., 2013). The developing vasculature of each resulting embryo was analysed blindly at 3 dpf, and genotypes were assigned to embryos after image acquisition (Fig. 8D, red). Whereas most WT siblings had normal ISV development, we observed an increased number of hypersprouting ISVs across the *notch1b-15<sup>uq1mf/+</sup>* and *notch1b-15<sup>uq1mf/1mf</sup>* population (Fig. 8E, asterisks; Fig. 8F, top) in a gene dosage-dependent manner, similar to the phenotype described previously in high MO concentration *notch1b* morphants and Notch signalling-deficient embryos (Geudens et al., 2010; Siekmann and Lawson, 2007). Further, mutant embryos also demonstrated loss of arterial connections between the dorsal aorta and dorsal longitudinal anastomotic vessel, similar to those described in Notch signalling-deficient zebrafish (Geudens et al., 2010; Quillien et al., 2014), while the *notch1b*-depleted *notch1b-15<sup>+/+</sup>* and *notch1b-15<sup>uq1mf/+</sup>* morphant embryos demonstrated an equal proportion of arterial and venous ISVs as previously reported (Bussmann et al., 2010) (Fig. 8E,F bottom).

To further confirm that interfering with *notch1b-15* enhancer activity is additive to *notch1b* transcript depletion, we chemically treated the *notch1b-15<sup>uq1mf/+</sup>* cross with DAPT, a well characterised Notch signalling inhibitor, over the course of endothelial differentiation (15- to 16-somite stage through to 3 dpf) (Fig. 8D, blue). All embryos treated with a suboptimal concentration of DAPT (5 µM) showed a straight body axis, indicating that somitogenesis (and therefore Notch activity) was not significantly compromised (Fig. S7A). Interestingly, despite this lack of morphological defects, F<sub>2</sub> fish homozygous for the *notch1b-15<sup>uq1mf</sup>* allele displayed a lower arterial-to-total ISV ratio (Fig. 8G, Fig. S7A). By contrast, fish homozygous for the *notch1b-15<sup>uq1mf</sup>* allele treated with DMSO vehicle alone had a comparable aISV ratio to both *notch1b-15<sup>+/+</sup>* and *notch1b-15<sup>uq1mf/+</sup>* siblings (Fig. S7B), similar to the untreated control. This suggests that the observed loss of aISV is specific to an additive effect of DAPT treatment and *notch1b-15* enhancer activity disruption. Overall, these data suggest a functional role of the *notch1b-15* enhancer in the endothelial-specific initiation of *notch1b* transcription to promote the acquisition of arterial cell identity.

#### SoxF factors are required for endogenous *Notch1/notch1b* expression

Our results have clearly implicated SoxF factors as direct upstream regulators of arterial Notch enhancers, and therefore suggest a considerably greater role for SoxF alone in the regulation of the Notch receptors than in the Notch ligands. However, since the *notch1b-15* enhancer is partially redundant with xxxxx xxxxx

xxxxx?, we wished to establish whether SoxF regulation is required for endogenous *notch1b* expression itself, not just enhancer activity. Further, our results so far do not entirely rule out the possibility of SoxF/Rbpj combinatorial regulation of *notch1b*, as was previously shown for *Dll4* enhancers (Sacilotto et al., 2013). Although neither the human *NOTCH1+16* nor the zebrafish *notch1b-15* enhancer contains conserved consensus Rbpj/Notch binding motifs, transcription factors can bind non-consensus motifs, and not all transcription factors necessarily bind conserved motifs (Wong et al., 2015). The nature of the SoxF/Notch combinatorial regulation of *Dll4*, where the SoxF or Rbpj binding motifs play functionally interchangeable roles, indicates potential direct interactions between these two proteins, such that only a single SoxF binding motif might be necessary for SoxF/Rbpj synergy. We therefore investigated the consequences of SoxF depletion on endogenous *Notch1/notch1b* expression *in vivo*.

Although *Sox17* is robustly expressed in arterial endothelial cells (Corada et al., 2013; Hosking et al., 2009), compound *Sox7;Sox18* deletion in mice resulted in a reduction of *Notch1* mRNA levels in the trunk dorsal aorta and primitive heart cavities of E8.5 embryos (Fig. 9A, Fig. S8A). These results concur with observations in the mouse retina, where the vascular phenotype after *Sox7;Sox17;Sox18* endothelial-specific triple deletion closely resembled defects caused by loss of Notch signalling (Zhou et al., 2015). Strikingly, both MO-induced gene knockdown and compound mutation of *sox7* and *sox18* in zebrafish embryos also led to a near-complete loss of *notch1b* transcript expression specifically in endothelial cells, as shown by *in situ* hybridisation analysis (Fig. 9B,C, Fig. S8B). These results further establish an essential role for SoxF transcription factors in the induction of *Notch1/notch1b* gene expression, and position SoxF proteins at the top of the transcriptional hierarchy regulating arterial specification.


#### DISCUSSION

Recent work has implicated SoxF, S and Rbpj, the Notch transcriptional effector, in the regulation of the Notch ligand *Dll4* and many other key arterial genes (Corada et al., 2013; Lizama et al., 2015; Sacilotto et al., 2013; Wythe et al., 2013), but has not established the hierarchical arrangement of these diverse factors in arterial specification and differentiation. In this study, we demonstrate that arterial expression of the Notch receptor *Notch1/notch1b*, a key player in arterial specification, is directly downstream of SoxF regulation in both fish and mouse. Unlike other key arterial specification markers, including *Dll4*, *Efnb2a* and *Dlc* (Sacilotto et al., 2013), ablation of *Notch1/Notch1b* expression after depletion of SoxF factors occurred without concurrent inhibition of Notch signalling. Therefore, this work positions SoxF factors directly above Notch signalling in the transcriptional hierarchy initiating arterial development, and suggests that SoxF factors might initiate a feed-forward loop directing arterial identity. In this model, SoxF factors would first activate Notch signalling via the transcriptional activation of Notch receptors in combination with weak activation of Notch ligands (Sacilotto et al., 2013). This early SoxF-mediated activity would then be boosted by the initiation of Notch signalling, resulting in the sustained activation of other downstream genes, eventually activating the full cohort of genes necessary to acquire and maintain arterial endothelial cell identity.

Understanding the function of SoxF factors through mutational analysis has presented significant challenges. Strain-specific variations in mice after depletion of individual SoxF genes and varying levels of compensation from other SoxF factors have

change to "SoxF in regulation of Notch receptors"

other *notch1b* shadow enhancers



**Fig. 9. Mouse and zebrafish arterial *Notch1* expression is dependent on SOX7/18 activity.** (A) Transverse sections of whole-mount *in situ* hybridisation for *Notch1* transcript on E8.5 mouse embryos shows a reduction of *Notch1* expression (asterisks) in the bulbus cordis (bc) region of the primitive heart and vitelline artery (va) of Sox7/Sox18 double knockouts. (B) At 24 hpf *notch1b* expression is significantly downregulated in the dorsal aorta (asterisks) of *sox7/sox18* double-morphant zebrafish, whereas its signal is unaffected in the neural tube. *flt1* expression is comparable between controls and *sox7/sox18* double morphants, indicating that the dorsal aorta is correctly formed. (C) *notch1b* was barely detectable in the dorsal aorta and ISVs of *sox7/18* double-knockout zebrafish (asterisks), as compared with the WT, *sox7* or *sox18* heterozygotes (arrows). The number of embryos showing the illustrated phenotype among the total examined is indicated. DA, dorsal aorta; PCV, posterior cardinal vein.

resulted in some contradictory reports (Corada et al., 2013; Lee et al., 2014), as is also the case for zebrafish morphant analysis (Cermenati et al., 2008; Herpers et al., 2008; Pendeville et al., 2008). Nonetheless, the results described here agree with an increasingly convincing body of work suggesting that SoxF factors influence Notch signalling yet are unaffected by Notch ablation. For example, overexpression of Sox17 upregulates components of the Notch pathway (Corada et al., 2013; Lizama et al., 2015), loss of functional SoxF factors results in defects similar to those observed after Notch inhibition in mice and fish (Corada et al., 2013; Sakamoto et al., 2007; Zhou et al., 2015), while Notch ablation results in little alteration to the endothelial expression of SoxF factors in mice and fish (Abdelilah et al., 1996; Corada et al., 2013). Data reported here combine with these reports to strongly support a role for SoxF factors as part of the initial transcriptional machinery that instructs arterial specification events.

However, some questions remain. In particular, it is notable that *sox7;sox18* double-mutant fish, although exhibiting severe arteriovenous defects very similar to those seen in Notch-deficient fish (Lawson et al., 2001), do not fully recapitulate the effects of Vegfa depletion on arterial specification (Lawson et al., 2002). While this difference may in part be attributed to weak expression of zebrafish *sox17*, which is expressed in some arterial endothelial cells (Hermkens et al., 2015), it is also expected that the Vegfa pathway has a wider effect on arterial endothelial cells more generally, away from SoxF-mediated activation of Notch signalling. SoxF factors are also influenced by signalling pathways beyond Vegfa. The diverse nature of Vegfa roles in the vasculature, including the regulation of both sprouting angiogenesis and arteriogenesis, processes that inevitably involve different cohorts of downstream targets, make it necessary that multiple regulatory pathways interact with Vegfa during vascular development. While recent work has shown that Vegfa signalling increases the nuclear translocation of SoxF (Duong et al., 2014), and inhibition of Vegfa results in the loss of vascular *sox7* in fish, *sox18* is still expressed in the absence of intact Vegfa signalling (Pendeville et al., 2008). Additionally, loss of the Vegf co-receptor Nrp1 has little effect on SoxF expression in mouse retinal vasculature (Zhou et al., 2015), pointing to other upstream influences on SoxF function in endothelial cells. Other upstream effectors of SoxF function are likely to include canonical Wnt signalling and Vegfd, both of which have been shown to influence SoxF factors (Corada et al., 2013; Duong et al., 2014; Zhou et al., 2015).

Recent evidence has also implicated a role for a coordinated Vegf-Mapk-Ets pathway in the induction of Notch signalling components and early arterial differentiation (Wythe et al., 2013). Notably, in addition to SoxF motifs, both the *Notch1* and *Dll4* enhancers share a number of highly conserved consensus motifs for the ETS family of transcription factors. While ETS motifs are common to all vascular enhancer elements, including many that are not preferentially expressed in the arterial vasculature (De Val and Black, 2009), the ETS factor Erg has been specifically implicated in arterial-specific regulation of *Dll4* (Wythe et al., 2013). It is therefore likely that Vegfa-mediated activation of ETS factors may contribute to the transcriptional activity of Notch downstream effectors, and thus may influence arterial establishment independently of SoxF factors. However, it is notable that Vegfa-mediated ETS transcription does not appear to be sufficient for arterial gene expression. *Dll4* enhancers lacking SoxF and Rbpj motifs but retaining all ETS motifs were unable to drive any transgene expression (Sacilotto et al., 2014). Notch enhancers lacking SoxF motifs (Figs 2–4) were found in other delineated arterial enhancers, including the *Ecel* upstream enhancer (Robinson et al., 2014) and the *Flkl* intron 10 enhancer, where loss of Rbpj-mediated repression resulted in expansion of enhancer activity into venous cells without alterations to ETS motif binding (Becker et al., 2016). Combined with recent observations demonstrating that Erg also plays a crucial role in venous specification through activation of *Aplnr* (Lathen et al., 2014), it is therefore likely that the role of Erg, and of other ETS factors, downstream of Vegfa in arterial-restricted gene expression occurs in co-operation with additional transcription factors. The data presented in this work, combined with the analysis of further arterial enhancers, including those of *Dll4* and *Ecel* (Robinson et al., 2014; Sacilotto et al., 2013; Wythe et al., 2013), increasingly suggest that SoxF may fulfil this role.



## MATERIALS AND METHODS

### Cloning

The 10×UAS:Sox18Ragged-mCherry plasmid was generated using the full-length mouse *Sox18Ragged* cDNA sequence, tagged with 10×UAS and mCherry and cloned into pDestTol2CG2 (xxx source? xxx). *notch1b-15:GFP* WT was generated by cloning a 1219 bp PCR fragment from zebrafish genomic DNA together with *gata2a* promoter and *GFP* reporter gene into the zebrafish enhancer detection (ZED) vector (Bessa et al., 2009). *notch1b-15mutSOX-a/b* was generated by site-directed PCR mutagenesis of the WT construct. The *NOTCH1-68*, *NOTCH1+3/5* and *NOTCH1+33* enhancers were generated by PCR from m<sup>mus</sup> genomic DNA, *NOTCH1+16* WT and *NOTCH1+16mutSOX-a/b* enhancers were generated as custom-made, double-stranded linear DNA fragments (GeneArt Strings, mammalian fragments were cloned into the *hsp68* (provided by N. Ahituv) (De Val et al., 2004). Primers fragments are listed in the supplementary Materials and Methods.

### Transgenic animals and genome editing

Animal procedures were approved by local ethical review and licensed by the UK Home Office or conformed to institutional guidelines of the University of Queensland Animal Ethics Committee. Transgenic mice were generated by oocyte microinjection and analysed as detailed in the supplementary Materials and Methods (De Val et al., 2004). Compound *Sox7<sup>-/-</sup>*; *Sox18<sup>-/-</sup>* (C57BL/6) mouse embryos were generated on the C57BL/6 background through crossing heterozygous *Sox7:tm1* to *Sox18:tm1* generating *Sox7<sup>+/-</sup>*; *Sox18<sup>+/-</sup>* mice, which were subsequently in-crossed (Pennisi et al., 2000a).

Transgenic zebrafish embryos were generated using the Tol2 system in conjunction with the ZED vector (Bessa et al., 2009). The *sox7<sup>hu5626</sup>*; *sox18<sup>hu10320</sup>* double-homozygous mutant zebrafish have been described previously (Hermkens et al., 2015). The *tg(fli1a:Gal4FF,10×UAS:Sox18Ragged-mCherry)* zebrafish line was generated by crossing 10×UAS: *Sox18Ragged-mCherry* with *fli1a:Gal4FF, 4×UAS* *Utrophin GFP*. MO-mediated knockdown was performed as previously described (Herpers et al., 2008). CRISPR genome editing for *notch1b-15* was performed as described by Gagnon et al. (2014) using the primers listed in the supplementary Materials and Methods to generate *notch1b-15<sup>uq1mf</sup>* (203

The F<sub>2</sub> *notch1b-15<sup>uq1mf/uq1mf</sup>* was generated by in-*15<sup>uq1mf/+</sup>*, while F<sub>3</sub> *notch1b-15<sup>uq1mf/uq1mf</sup>* was generated from *15<sup>uq1mf/uq1mf</sup>* in-cross, both in the *tg(fli1:YFP;hsp1:dsRed)*

### Chromatin immunoprecipitation (ChIP)

Positive *tg(fli1a:Gal4FF;10×UAS:Sox18Ragged-mCherry)* fish larvae were collected at 26-28 hpf and treated as previously described (Mohammed et al., 2013). DNA amplification was performed using the TruSeq ChIP-seq Kit (Illumina, IP-202-1012) following immunoprecipitation. The library was quantified using the KAPA library quantification kit for Illumina sequencing platforms (KAPA Biosystems, KK4824) and 50 bp single-end reads were sequenced on a HiSeq 2500 (Illumina) following the manufacturer's protocol. FASTQ files were mapped to GRCz10/danRer10 genome assembly using bowtie (xxxxx citation? xxxxx), and peaks were called using MACS version 2.1.0. using input as a reference. To avoid false-positive peaks calling due to the mCherry epitope, ChIP-seq with the mCherry epitope only was performed in parallel to *SOX18Ragged-mCherry* ChIP-seq and peaks called in these experimental conditions were subtracted from the peaks called in the *SOX18Ragged-mCherry* conditions. For details, see the supplementary Materials and Methods.

### Motif identification and EMSA

Sequences were analysed for consensus sequence motifs by eye and using TRANSFAC (BIOBASE; [www.biobase-international.com/transcription-factor-binding-sites](http://www.biobase-international.com/transcription-factor-binding-sites)) (Matys et al., 2006). EMSAs were performed as previously described (De Val et al., 2004), as outlined in the supplementary Materials and Methods.

### Morpholinos and drug treatment

MO-mediated knockdown was performed as previously described (xxxxx citation? xxxxx). ATG MOs against *sox7* and *sox18* were injected into the

(*notch1b-15:GFP*) stable line at the 1-2 cell stage at 5 ng/embryo (Herpers et al., 2008). To assess the effect of *sox7/18* knockdown on endogenous *notch1b* transcripts, *sox7* and *sox18* MOs were injected into WT zebrafish larvae at 1 ng/embryo in parallel with a standard control MO (std-MO) injected at 2 ng/embryo (Cermenati et al., 2008). To characterise *notch1b-15<sup>uq1mf</sup>*, *notch1b* MO was injected into the *notch1b-15<sup>uq1mf/+</sup>* cross at 5 ng/embryo. For MO sequences, see the supplementary Materials and Methods. N-[(3,5-difluorophenyl)acetyl]-L-alanyl-2-phenylglycine-1,1-dimethylethyl ester (DAPT; xxx source? xxx) was used at 5 μM dissolved in 1% DMSO. Fish were treated from the 15- to 16-somite stage to 3 dpf and the medium containing DAPT was refreshed daily.

### In situ hybridisation and immunofluorescence staining

Whole-mount *in situ* hybridisation in zebrafish larvae was performed as described (Coxam et al., 2015; Duong et al., 2014). Section and whole-mount *in situ* hybridisation in mouse was performed as described (Metzis et al., 2013; Fowles et al., 2003). The *Notch1* probe was generated by PCR from mouse embryo cDNA pool at E14.5, and reverse transcribed with T7 polymerase. Whole-mount immunohistochemistry for anti-GFP was performed as described (Koltowska et al., 2015). For details, see the supplementary Materials and Methods.

### Quantification and data analysis

To characterise the vasculature in Fig. 8E-G and Figs S6, S7, intersomitic vessels (20-22 ISVs) expressing *tg(fli1:YFP)* were analysed across 10-11 somites through a z-stack using ImageJ (NIH) after image acquisition by confocal microscopy. Intersomitic vessels connecting the dorsal longitudinal anastomotic vessel to the dorsal aorta expressing YFP were assigned as arterial ISVs. Vessels were also scored for ectopic sprouting. The proportion of aISVs or hypersprouts among the total number of ISVs was analysed by two-tailed Mann-Whitney U-test. To quantify the GFP intensity of *tg(notch1b-15:GFP)* and *tg(notch1b-15mutSOX-a/b:GFP)* (Fig. 7A), two to three ISVs across five to six somites in the trunk region were analysed using ImageJ. A region of interest (ROI) covering a single mean pixel intensity for each ISV was quantified back across three z-sections. This value was further subtracted from the background value. Average ISV GFP intensity from two to three ISVs for each fish larva was used for its genomic GFP copy number. A similar method was used to quantify GFP intensity in the endothelial lining along the dorsal aorta.

### Fluorescence-activated cell sorting (FACS) and expression analysis

Fli1:YFP-positive endothelial cells were isolated from WT and F<sub>3</sub> *notch1b-15<sup>uq1mf/uq1mf</sup>* at 24-28 hpf. RNA was extracted, amplified and cDNA was synthesized as previously described (Coxam et al., 2014; Picelli et al., 2014). Primer sequences and details of the quantitative PCR analysis are provided in the supplementary Materials and Methods.

### Acknowledgement

We thank M. Shipman for help with imaging. The ZED vector was kindly provided by F. Tessadori (Bakkers lab, Hubrecht Institute). The *notch1b* plasmid used to generate the probe was kindly provided by N. D. Lawson (University of Massachusetts Medical School).

### Competing interests

The authors declare no competing or financial interests.

### Author contributions

Conceptualization: I.K.-N.C., M.Frit., S.D.V., M.Fran.; Methodology: I.K.-N.C., M.Frit., S.D.V.; M.Fran.; Formal analysis: K.H., J.C.; Investigation: I.K.-N.C., M.Frit., C.P.-T., A.N., K.H., A.L., J.O., D.D., A.O., D.H., E.L., K.L., I.R., M.C., B.H.; Resources: A.L., G.B.-G., J.C., S.S.-M., M.B.; Data curation: K.H., J.C.; Writing - original draft: I.K.-N.C., S.D.V., M.Fran.; Writing - review & editing: I.K.-N.C., B.H., M.B., S.D.V., M.Fran.; Visualization: I.K.-N.C., S.D.V., M.Fran.; Supervision: G.B.-G., J.C., E.D., B.H., M.B., S.D.V., M.Fran.; Project administration: S.D.V., M.Fran.; Funding acquisition: S.D.V., M.B., M.Fran.

is this correct Sarah?

change to 'processed as described in supplementary materials and methods'

Sarah please take note

please cite Langmead et al., 2010. PMC3010897

Please cite Duong et al 2014 PMID 24269955 and Cermenati et al 2008 PMID: 18094332

Area to be deleted has been indicated in sup pdf

in the ArrayExpress database at EMBL-EBI ([www.ebi.ac.uk/arrayexpress](http://www.ebi.ac.uk/arrayexpress))

**RESEARCH ARTICLE**

**AQ28** Funding

1118 This work was supported by the National Health and Medical Research Council of

1119 Australia (NHMRC) (APP1107643); The Cancer Council Queensland (1107631) (M.

**AQ29** 1120 Fran.); the Australian Research Council **Discovery Project** (DP140100485) and a

1121 Career Development Fellowship (APP1111169) (M.Fran.); the Ludwig Institute for

1122 Cancer Research (M.Frit., A.N., J.R., S.D.V.); the Medical Research Council (MR/

1123 J007765/1) (K.L., G.B.-G., S.D.V.); the Fondazione Cariplo (2011-0555) (M.B., B.H.,

1124 M.Fran.); and the Biotechnology and Biological Sciences Research Council (BB/

1125 L020238/1) (A.N., K.L., G.B.-G., S.D.V.). Deposited in PMC for release after 6

months.

**AQ30** Data availability

1127 ChIP-seq data are available at **xxxxx xxxxx** with accession number **xxxxx xxxxx**.

1128

1129 **Supplementary information**

1130 Supplementary information available online at

1131 <http://dev.biologists.org/lookup/doi/10.1242/dev.146241.supplemental>

1132

1133 **References**

1134 **Abdellilah, S., Mountcastle-Shah, E., Harvey, M., Solnica-Krezel, L., Schier,**

1135 **A. F., Stemple, D. L., Malicki, J., Neuhauss, S. C., Zwartkruis, F., Stainier, D. Y.**

1136 **et al. (1996). Mutations affecting neural survival in the zebrafish *Danio rerio*.**

1137 ***Development* **123**, 217-227.**

1138 **Becker, P. W., Sacilotto, N., Nornes, S., Neal, A., Thomas, M. O., Liu, K., Preece,**

1139 **C., Ratnayaka, I., Davies, B., Bou-Gharios, G. et al. (2016). An intronic *Flk1***

1140 **enhancer directs arterial-specific expression via RBPJ-mediated venous**

1141 **repression. *Arterioscler. Thromb. Vasc. Biol.* **36**, 1209-1219.**

1142 **Bessa, J., Tena, J. J., de la Calle-Mustienes, E., Fernández-Miñán, A., Naranjo,**

1143 **S., Fernández, A., Montoliu, L., Akalin, A., Lenhard, B., Casares, F. et al.**

1144 **(2009). Zebrafish enhancer detection (ZED) vector: a new tool to facilitate**

1145 **transgenesis and the functional analysis of cis-regulatory regions in zebrafish.**

1146 ***Dev. Dyn.* **238**, 2409-2417.**

1147 **Bogdanović, O., Fernández-Miñán, A., Tena, J. J., de la Calle-Mustienes, E.,**

1148 **Hidalgo, C., van Kruysbergen, I., van Heeringen, S. J., Veenstra, G. J. C. and**

1149 **Gómez-Skarmeta, J. L. (2012). Dynamics of enhancer chromatin signatures**

1150 **mark the transition from pluripotency to cell specification during embryogenesis.**

1151 ***Genome Res.* **22**, 2043-2053.**

1152 **Bray, S. J. (2006). Notch signalling: a simple pathway becomes complex. *Nat. Rev.***

1153 ***Mol. Cell Biol.* **7**, 678-689.**

1154 **Bussmann, J., Bos, F. L., Urasaki, A., Kawakami, K., Duckers, H. J. and**

1155 **Schulte-Merker, S. (2010). Arteries provide essential guidance cues for**

1156 **lymphatic endothelial cells in the zebrafish trunk. *Development* **137**, 2653-2657.**

1157 **Cannavò, E., Khoueiry, P., Garfield, D. A., Geeleher, P., Zichner, T., Gustafson,**

1158 **E. H., Ciglar, L., Korb, J. O. and Furlong, E. E. M. (2016). Shadow enhancers**

1159 **are pervasive features of developmental regulatory networks. *Curr. Biol.* **26**,**

1160 **38-51.**

1161 **Carmeliet, P., Ferreira, V., Breier, G., Pollefeyt, S., Kieckens, L., Gertsenstein,**

1162 **M., Fahrig, M., Vandenhoek, A., Harpal, K., Eberhardt, C. et al. (1996).**

1163 **Abnormal blood vessel development and lethality in embryos lacking a single**

1164 ***VEGF* allele. *Nature* **380**, 435-439.**

1165 **Cermenati, S., Molero, S., Cimbro, S., Corti, P., Del Gaudio, L., Amodeo, R.,**

1166 **Dejana, E., Koopman, P., Cotelli, F. and Beltrame, M. (2008). *Sox18* and *Sox7***

1167 **play redundant roles in vascular development. *Blood* **111**, 2657-2666.**

1168 **Chong, D. C., Koo, Y., Xu, K., Fu, S. and Cleaver, O. (2011). Stepwise**

1169 **arteriovenous fate acquisition during mammalian vasculogenesis. *Dev. Dyn.* **240**,**

1170 **2153-2165.**

1171 **Corada, M., Orsenigo, F., Morini, M. F., Pitulescu, M. E., Bhat, G., Nyqvist, D.,**

1172 **Resnais, F., Conti, V., Briot, A., Iruela-Arispe, M. L. et al. (2013). *Sox17* is**

1173 **indispensable for acquisition and maintenance of arterial identity. *Nat. Commun.***

1174 ****4**, 2609.**

1175 **Coxam, B., Sabine, A., Bower, N. I., Smith, K. A., Pichol-Thievend, C.,**

1176 **Skoczylas, R., Astin, J. W., Frampton, E., Jaquet, M., Crosier, P. S. et al.**

1177 **(2014). *Pkd1* regulates lymphatic vascular morphogenesis during development.**

1178 ***Cell Rep.* **7**, 623-633.**

1179 **Coxam, B., Neyt, C., Grassini, D. R., Le Guen, L., Smith, K. A., Schulte-Merker,**

1180 **S. and Hogan, B. M. (2015). carbamoyl-phosphate synthetase 2, aspartate**

1181 **transcarbamylase, and dihydroorotase (*cad*) regulates Notch signaling and**

1182 **vascular development in zebrafish. *Dev. Dyn.* **244**, 1-9.**

1183 **De Val, S. and Black, B. L. (2009). Transcriptional control of endothelial cell**

1184 **development. *Dev. Cell* **16**, 180-195.**

1185 **De Val, S., Anderson, J. P., Heidt, A. B., Kiem, D., Xu, S.-M. and Black, B. L.**

1186 **(2004). *Mef2c* is activated directly by Ets transcription factors through an**

1187 **evolutionarily conserved endothelial cell-specific enhancer. *Dev. Biol.* **275**,**

1188 **424-434.**

1189 **Duarte, A., Hirashima, M., Benedito, R., Trindade, A., Diniz, P., Bekman, E.,**

1190 **Costa, L., Henrique, D. and Rossant, J. (2004). Dosage-sensitive requirement**

1191 **for mouse *Dil4* in artery development. *Genes Dev.* **18**, 2474-2478.**

E-MTAB-5843.  
please note that it  
is still under  
curation as of  
today

**Duong, T., Koltowska, K., Pichol-Thievend, C., Le Guen, L., Fontaine, F., Smith,**

**K. A., Truong, V., Skoczylas, R., Stacker, S. A., Achen, M. G. et al. (2014).**

***VEGFD* regulates blood vascular development by modulating *SOX18* activity.**

***Blood* **123**, 1102-1112.**

**Fowles, L. F., Bennetts, J. S., Berkman, J. L., Williams, E., Koopman, P.,**

**Teasdale, R. D. and Wicking, C. (2003). Genomic screen for genes involved in**

**mammalian craniofacial development. *Genesis* **35**, 73-87.**

**François, M., Caprini, A., Hosking, B., Orsenigo, F., Wilhelm, D., Browne, C.,**

**Paavonen, K., Karnezis, T., Shayan, R., Downes, M. et al. (2008). *Sox18***

**induces development of the lymphatic vasculature in mice. *Nature* **456**, 643-647.**

**François, M., Koopman, P. and Beltrame, M. (2010). *SoxF* genes: Key players in**

**the development of the cardio-vascular system. *Int. J. Biochem. Cell Biol.* **42**,**

**445-448.**

**Gagnon, J. A., Valen, E., Thyme, S. B., Huang, P., Akhmetova, L. Pauli, A.,**

**Montague, T. G., Zimmerman, S., Richter, C. and Schier, A. F. (2014). Efficient**

**mutagenesis by Cas9 protein-mediated oligonucleotide insertion and large-scale**

**assessment of single-guide RNAs. *PLoS ONE* **9**, e98186.**

**Gale, N. W., Dominguez, M. G., Noguera, I., Pan, L., Hughes, V., Valenzuela,**

**D. M., Murphy, A. J., Adams, N. C., Lin, H. C., Holash, J. et al. (2004).**

**Haploinsufficiency of delta-like 4 ligand results in embryonic lethality due to major**

**defects in arterial and vascular development. *Proc. Natl. Acad. Sci. USA* **101**,**

**15949-15954.**

**Geudens, I., Herpers, R., Hermans, K., Segura, I., Ruiz de Almodovar, C.,**

**Bussmann, J., De Smet, F., Vandevelde, W., Hogan, B. M., Siekmann, A. et al.**

**(2010). Role of delta-like-4/Notch in the formation and wiring of the lymphatic**

**network in zebrafish. *Arterioscler. Thromb. Vasc. Biol.* **30**, 1695-1702.**

**Gore, A. V., Monzo, K., Cha, Y. R., Pan, W. and Weinstein, B. M. (2012). Vascular**

**development in the zebrafish. *Cold Spring Harb. Perspect. Med.* **2**,**

**a006684-a006684.**

**Harvey, S. A., Sealy, I., Kettleborough, R., Fényes, F., White, R., Stemple, D. and**

**Smith, J. C. (2013). Identification of the zebrafish maternal and paternal**

**transcriptomes. *Development* **140**, 2703-2710.**

**Heintzman, N. D. and Ren, B. (2009). Finding distal regulatory elements in the**

**human genome. *Curr. Opin. Genet. Dev.* **19**, 541-549.**

**Hermkens, D. M. A., van Impel, A., Urasaki, A., Bussmann, J., Duckers, H. J.**

**and Schulte-Merker, S. (2015). *Sox7* controls arterial specification in conjunction**

**with *hey2* and *efnb2* function. *Development* **142**, 1695-1704.**

**Herpers, R., van de Kamp, E., Duckers, H. J. and Schulte-Merker, S. (2008).**

**Redundant roles for *Sox7* and *Sox18* in arteriovenous specification in zebrafish.**

***Circ. Res.* **102**, 12-15.**

**Hollenhorst, P. C., McIntosh, L. P. and Graves, B. J. (2011). Genomic and**

**biochemical insights into the specificity of ETS transcription factors. *Annu. Rev.***

***Biochem.* **80**, 437-471.**

**Hosking, B., François, M., Wilhelm, D., Orsenigo, F., Caprini, A., Svingen, T.,**

**Tutt, D., Davidson, T., Browne, C., Dejana, E. et al. (2009). *Sox7* and *Sox17* are**

**strain-specific modifiers of the lymphangiogenic defects caused by *Sox18***

**dysfunction in mice. *Development* **136**, 2385-2391.**

**Jahnsen, E. D., Trindade, A., Zaun, H. C., Lehoux, S., Duarte, A. and Jones,**

**E. A. V. (2015). *Notch1* is pan-endothelial at the onset of flow and regulated by**

**flow. *PLoS ONE* **10**.**

**Kent, W. J., Sugnet, C. W., Furey, T. S., Roskin, K. M., Pringle, T. H., Zahler, A. M.**

**and Haussler, D. (2002). The human genome browser at UCSC. *Genome Res.***

****12**, 996-1006.**

**Kim, K., Kim, I.-K., Yang, J. M., Lee, E., Koh, B. I., Song, S., Park, J., Lee, S.,**

**Choi, C., Kim, J. W. et al. (2016). *SoxF* transcription factors are positive feedback**

**regulators of VEGF signaling. *Circ. Res.* **119**, 839-852.**

**Koltowska, K., Paterson, S., Bower, N. I., Baillie, G. J., Lagendijk, A. K., Astin,**

**J. W., Chen, H., François, M., Crosier, P. S., Taft, R. J. et al. (2015). *mafb* is a**

**downstream transcriptional effector of *Vegfc* signaling essential for embryonic**

**lymphangiogenesis in zebrafish. *Genes Dev.* **29**, 1618-1630.**

**Krebs, L. T., Xue, Y., Norton, C. R., Shutter, J. R., Maguire, M., Sundberg, J. P.,**

**Gallahan, D., Closson, V., Kitajewski, J., Callahan, R. et al. (2000). Notch**

**signaling is essential for vascular morphogenesis in mice. *Genes Dev.* **14**,**

**1343-1352.**

**Krebs, L. T., Shutter, J. R., Tanigaki, K., Honjo, T., Stark, K. L. and Gridley, T.**

**(2004). Haploinsufficient lethality and formation of arteriovenous malformations in**

**Notch pathway mutants. *Genes Dev.* **18**, 2469-2473.**

**Lanahan, A. A., Hermans, K., Claes, F., Kerley-Hamilton, J. S., Zhuang, Z. W.,**

**Giordano, F. J., Carmeliet, P. and Simons, M. (2010). VEGF receptor 2**

**endocytic trafficking regulates arterial morphogenesis. *Dev. Cell* **18**, 713-724.**

**Lathen, C., Zhang, Y., Chow, J., Singh, M., Lin, G., Nigam, V., Ashraf, Y. A.,**

**Yuan, J. X., Robbins, I. M. and Thistlethwaite, P. A. (2014). ERG-APLN axis**

**controls pulmonary venule endothelial proliferation in pulmonary Venous-occlusive**

**disease. *Circulation* **130**, 1179-1191.**

**Lawson, N. D. (2003). phospholipase C gamma-1 is required downstream of**

**vascular endothelial growth factor during arterial development. *Genes Dev.* **17**,**

**1346-1351.**

**Lawson, N. D., Scheer, N., Pham, V. N., Kim, C. H., Chitnis, A. B., Campos-**

**Ortega, J. A. and Weinstein, B. M. (2001). Notch signaling is required for arterial-**



- venous differentiation during embryonic vascular development. *Development* **128**, 3675-3683.
- Lawson, N. D., Vogel, A. M. and Weinstein, B. M. (2002). sonic hedgehog and vascular endothelial growth factor act upstream of the Notch pathway during arterial endothelial differentiation. *Dev. Cell* **3**, 127-136.
- Lee, S.-H., Lee, S., Yang, H., Song, S., Kim, K., Saunders, T. L., Yoon, J. K., Koh, G. Y. and Kim, I. (2014). Notch pathway targets proangiogenic regulator Sox17 to restrict angiogenesis. *Circ. Res.* **115**, 215-226.
- Liu, Z.-J., Shirakawa, T., Li, Y., Soma, A., Oka, M., Dotto, G. P., Fairman, R. M., Velazquez, O. C. and Herlyn, M. (2003). Regulation of Notch1 and Dll4 by vascular endothelial growth factor in arterial endothelial cells: implications for modulating arteriogenesis and angiogenesis. *Mol. Cell. Biol.* **23**, 14-25.
- Lizama, C. O., Hawkins, J. S., Schmitt, C. E., Bos, F. L., Zape, J. P., Cautivo, K. M., Borges Pinto, H., Rhyner, A. M., Yu, H., Donohoe, M. E. et al. (2015). Repression of arterial genes in hemogenic endothelium is sufficient for haematopoietic fate acquisition. *Nat. Commun.* **6**, 7739.
- Matys, V., Kel-Margoulis, O. V., Fricke, E., Liebich, I., Land, S., Barre-Dirrie, A., Reuter, I., Chekmenev, D., Krull, M., Hornischer, K. et al. (2006). TRANSFAC and its module TRANSCOMP: transcriptional gene regulation in eukaryotes. *Nucleic Acids Res.* **34**, D108-D110.
- Mertin, S., McDowall, S. G. and Harley, V. R. (1999). The DNA-binding specificity of SOX9 and other SOX proteins. *Nucleic Acids Res.* **27**, 1359-1364.
- Metzis, V., Courtney, A. D., Kerr, M. C., Ferguson, C., Rondon Galeano, M. C., Parton, R. G., Wainwright, B. J. and Wicking, C. (2013). Patched1 is required in neural crest cells for the prevention of orofacial clefts. *Hum. Mol. Genet.* **22**, 5026-5035.
- Mohammed, H., D'Santos, C., Serandour, A. A., Ali, H. R., Brown, G. D., Atkins, A., Rueda, O. M., Holmes, K. A., Theodorou, V., Robinson, J. L. L. et al. (2013). Endogenous purification reveals GREB1 as a key estrogen receptor regulatory factor. *Cell Rep.* **3**, 342-349.
- Pendeville, H., Winandy, M., Manfroid, I., Nivelles, O., Motte, P., Pasque, V., Peers, B., Struman, I., Martial, J. A. and Voz, M. L. (2008). Zebrafish Sox7 and Sox18 function together to control arterial-venous identity. *Dev. Biol.* **317**, 405-416.
- Pennisi, D., Bowles, J., Nagy, A., Muscat, G. and Koopman, P. (2000a). Mice null for Sox18 are viable and display a mild coat defect. *Mol. Cell. Biol.* **20**, 9331-9336.
- Pennisi, D., Gardner, J., Chambers, D., Hosking, B., Peters, J., Muscat, G., Abbott, C. and Koopman, P. (2000b). Mutations in Sox18 underlie cardiovascular and hair follicle defects in ragged mice. *Nat. Genet.* **24**, 434-437.
- Phng, L.-K. and Gerhardt, H. (2009). Angiogenesis: a team effort coordinated by notch. *Dev. Cell* **16**, 196-208.
- Picelli, S., Faridani, O. R., Björklund, A. K., Winberg, G., Sagasser, S. and Sandberg, R. (2014). Full-length RNA-seq from single cells using Smart-seq2. *Nat. Protoc.* **9**, 171-181.
- Quillien, A., Moore, J. C., Shin, M., Siekmann, A. F., Smith, T., Pan, L., Moens, C. B., Parsons, M. J. and Lawson, N. D. (2014). Distinct Notch signaling outputs pattern the developing arterial system. *Development* **141**, 1544-1552.
- Robinson, A. S., Materna, S. C., Barnes, R. M., De Val, S., Xu, S.-M. and Black, B. L. (2014). An arterial-specific enhancer of the human endothelin converting enzyme 1 (ECE1) gene is synergistically activated by Sox17, FoxC2, and Etv2. *Dev. Biol.* **395**, 379-389.
- Roca, C. and Adams, R. H. (2007). Regulation of vascular morphogenesis by Notch signaling. *Genes Dev.* **21**, 2511-2524.
- Sabo, P. J., Hawrylycz, M., Wallace, J. C., Humbert, R., Yu, M., Shafer, A., Kawamoto, J., Hall, R., Mack, J., Dorschner, M. O. et al. (2004). Discovery of functional noncoding elements by digital analysis of chromatin structure. *Proc. Natl. Acad. Sci. USA* **101**, 16837-16842.
- Sacilotto, N., Monteiro, R., Fritzsche, M., Becker, P. W., Sanchez-del-Campo, L., Liu, K., Pinheiro, P., Ratnayaka, I., Davies, B., Goding, C. R. et al. (2013). Analysis of Dll4 regulation reveals a combinatorial role for Sox and Notch in arterial development. *Proc. Natl. Acad. Sci. USA* **110**, 11893-11898.
- Sakamoto, Y., Hara, K., Kanai-Azuma, M., Matsui, T., Miura, Y., Tsunekawa, N., Kurohmaru, M., Saijoh, Y., Koopman, P. and Kanai, Y. (2007). Redundant roles of Sox17 and Sox18 in early cardiovascular development of mouse embryos. *Biochem. Biophys. Res. Commun.* **360**, 539-544.
- Siekmann, A. F. and Lawson, N. D. (2007). Notch signalling limits angiogenic cell behaviour in developing zebrafish arteries. *Nature* **445**, 781-784.
- Visconti, R. P., Richardson, C. D. and Sato, T. N. (2002). Orchestration of angiogenesis and arteriovenous contribution by angiopoietins and vascular endothelial growth factor (VEGF). *Proc. Natl. Acad. Sci. USA* **99**, 8219-8224.
- Wong, E. S., Thybert, D., Schmitt, B. M., Stefflova, K., Odom, D. T. and Flicek, P. (2015). Decoupling of evolutionary changes in transcription factor binding and gene expression in mammals. *Genome Res.* **25**, 167-178.
- Wu, J., Iwata, F., Grass, J. A., Osborne, C. S., Elnitski, L., Fraser, P., Ohneda, O., Yamamoto, M. and Bresnick, E. H. (2005). Molecular determinants of NOTCH4 transcription in vascular endothelium. *Mol. Cell. Biol.* **25**, 1458-1474.
- Wythe, J. D., Dang, L. T. H., Devine, W. P., Boudreau, E., Artap, S. T., He, D., Schachterle, W., Stainier, D. Y. R., Oettgen, P., Black, B. L. et al. (2013). ETS factors regulate Vegf-dependent arterial specification. *Dev. Cell* **26**, 45-58.
- Zhou, Y., Williams, J., Smallwood, P. M. and Nathans, J. (2015). Sox7, Sox17, and Sox18 cooperatively regulate vascular development in the mouse retina. *PLoS ONE* **10**, e0143650.
- Zhou, P., Gu, F., Zhang, L., Akerberg, B. N., Ma, Q., Li, K., He, A., Lin, Z., Stevens, S. M., Zhou, B. et al. (2017). Mapping cell type-specific transcriptional enhancers using high affinity, lineage-specific Ep300 bioChIP-seq. *eLife* **6**, e22039.

## Funding details

S.No.	Funder name	Funder ID	Grant ID
1	National Health and Medical Research Council	<a href="http://dx.doi.org/10.13039/501100000925">http://dx.doi.org/10.13039/501100000925</a>	APP1107643
2	Cancer Council Queensland	<a href="http://dx.doi.org/10.13039/501100001168">http://dx.doi.org/10.13039/501100001168</a>	1107631
3	Australian Research Council	<a href="http://dx.doi.org/10.13039/501100000923">http://dx.doi.org/10.13039/501100000923</a>	DP140100485 APP1111169
4	Ludwig Institute for Cancer Research	<a href="http://dx.doi.org/10.13039/100009729">http://dx.doi.org/10.13039/100009729</a>	
5	Medical Research Council	<a href="http://dx.doi.org/10.13039/501100000265">http://dx.doi.org/10.13039/501100000265</a>	MR/J007765/1
6	Fondazione Cariplo	<a href="http://dx.doi.org/10.13039/501100002803">http://dx.doi.org/10.13039/501100002803</a>	2011-0555
7	Biotechnology and Biological Sciences Research Council	<a href="http://dx.doi.org/10.13039/501100000268">http://dx.doi.org/10.13039/501100000268</a>	BB/L020238/1